| 摘要 |
PURPOSE:A dry pharmaceutical, obtained by blending a dry tissue plasminogen activator as a principal ingredient with arginine and albumin as a stabilizer and having enhanced stability. CONSTITUTION:A dry pharmaceutical of a dry tissue plasminogen activator (hereinafter abbreviated to TPA) obtained by blending the TPA as a principal ingredient with at least one selected from arginine and salts thereof and albumin as a stabilizer. Although urokinase has been conventionally used as the plasminogen activator, the TPA having a molecular weight and antigenicity different from those of the urokinase has better affinity for fibrin than that of the urokinase and high value as a medicine. The TPA is unstable in any of a solvent in a purification step, at the time of freeze drying and during storage. The stability is enhanced by adding the above-mentioned arginine and albumin together. The amounts of the former and the latter are respectively 20-50mg and 10-100mg based on 2ml TPA solution.
|
